News Tag: RTOG 9802

NRG Oncology Currents October 2019 eNewsletter

Read More

Analyses of NRG Oncology/RTOG 9802 Suggests Both IDH-mutant WHO-defined Molecular Subgroups of High-risk Low-Grade Gliomas May Benefit from the Addition of PCV Chemotherapy to Radiotherapy

Read More